Hypercholesterolemia links hematopoiesis with atherosclerosis

Trends in Endocrinology and Metabolism

Volumn 24, Issue 3, 2013, Pages 129-136

  Soehnlein, Oliver ^a,b   Swirski, Filip K ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Hematopoietic stem and progenitor cells; Hypercholesterolemia; Monocytes; Neutrophils

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; APOLIPOPROTEIN A1; CHEMOKINE RECEPTOR CXCR4; CYCLODEXTRIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 17; INTERLEUKIN 3; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN; STROMAL CELL DERIVED FACTOR 1;

ATHEROSCLEROSIS; BONE MARROW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL EXPANSION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; GENE MUTATION; GRANULOPOIESIS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; LIPID DIET; LIPID STORAGE; MACROPHAGE; MESENCHYMAL STEM CELL; METABOLISM; MONOCYTOSIS; MORTALITY; MYELOPOIESIS; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHILIA; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTE; PHAGOCYTOSIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ATHEROSCLEROSIS; FOAM CELLS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; MONOCYTES; ORPHAN NUCLEAR RECEPTORS;

EID: 84875276500     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.10.008     Document Type: Review

References (100)

1. Rader D.J., Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008, 451:904-913.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
3. Thomas H.E., et al. Cholesterol-phospholipid ratio in the prediction of coronary heart disease. The Framingham study. N. Engl. J. Med. 1966, 274:701-705.
4. Berenson G.S., et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 1998, 338:1650-1656.
5. Nissen S.E., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 2005, 352:29-38.
6. Egusa G., Yamane K. Lifestyle, serum lipids and coronary artery disease: comparison of Japan with the United States. J. Atheroscler. Thromb. 2004, 11:304-312.
7. Mills G.L., Taylaur C.E. The distribution and composition of serum lipoproteins in eighteen animals. Comp. Biochem. Physiol. B. 1971, 40:489-501.
8. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
9. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
10. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ. Res. 2012, 110:875-888.
11. Geissmann F., et al. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
12. Passlick B., et al. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989, 74:2527-2534.
13. Swirski F.K., et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 2007, 117:195-205.
14. Libby P., et al. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
15. Soehnlein O., et al. Functional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis. J. Cell. Mol. Med. 2009, 13:4293-4303.
16. Friedman G.D., et al. The leukocyte count as a predictor of myocardial infarction. N. Engl. J. Med. 1974, 290:1275-1278.
17. Olivares R., et al. Monocyte count: a risk factor for coronary heart disease?. Am. J. Epidemiol. 1993, 137:49-53.
18. Sweetnam P.M., et al. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am. J. Epidemiol. 1997, 145:416-421.
19. Guasti L., et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb. Haemost. 2011, 106:591-599.
20. Tacke F., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 2007, 117:185-194.
21. Combadière C., et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008, 117:1649-1657.
22. Drechsler M., et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010, 122:1837-1845.
23. Döring Y., et al. Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1613-1623.
24. Rothe G., et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 1996, 16:1437-1447.
25. Tani S., et al. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am. J. Cardiol. 2009, 104:464-469.
26. Eash K.J., et al. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J. Clin. Invest. 2010, 120:2423-2431.
27. Martin C., et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003, 19:583-593.
28. Kim C.S., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int. J. Obes. 2006, 30:1347-1355.
29. Boisvert W.A., et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 1998, 101:353-363.
30. Zernecke A., et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ. Res. 2008, 102:209-217.
31. Serbina N.V., Pamer E.G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 2006, 7:311-317.
32. Shi C., et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 2011, 34:590-601.
33. Tsou C.L., et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 2007, 117:902-909.
34. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
35. -/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008, 117:1642-1648.
36. Yvan-Charvet L., et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 2007, 117:3900-3908.
37. Out R., et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 2008, 28:258-264.
38. Yvan-Charvet L., et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010, 328:1689-1693.
39. Murphy A.J., et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 2011, 121:4138-4149.
40. Bellosta S., et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 1995, 96:2170-2179.
41. Linton M.F., et al. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995, 267:1034-1037.
42. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
43. Janowski B.A., et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
44. Zhao C., Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J. Endocrinol. 2010, 204:233-240.
45. Joseph S.B., et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
46. Castrillo A., et al. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 2003, 278:10443-10449.
47. Ogawa D., et al. Liver X receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ. Res. 2005, 96:e59-e67.
48. Ghisletti S., et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009, 23:681-693.
49. A-Gonzalez N., et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31:245-258.
50. Marathe C., et al. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. J. Biol. Chem. 2006, 281:32197-32206.
51. Tangirala R.K., et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11896-11901.
52. Teupser D., et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2009-2015.
53. Hong C., et al. Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. J. Clin. Invest. 2012, 122:337-347.
54. Stark M.A., et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005, 22:285-294.
55. Smith E., et al. IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice. J. Immunol. 2007, 179:8274-8279.
56. Mercier F.E., et al. The bone marrow at the crossroads of blood and immunity. Nat. Rev. Immunol. 2011, 12:49-60.
57. Wilson A., Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 2006, 6:93-106.
58. Swirski F.K., et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325:612-616.
59. Robbins C.S., et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation 2012, 125:364-374.
60. Dutta P., et al. Myocardial infarction accelerates atherosclerosis. Nature 2012, 487:325-329.
61. Westerterp M., et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012, 11:195-206.
62. Suárez-álvarez B., et al. Mobilization and homing of hematopoietic stem cells. Adv. Exp. Med. Biol. 2012, 741:152-170.
63. Sugiyama T., et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
64. Koenen R.R., Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol. Med. 2011, 3:713-725.
65. Ling S., et al. Cell adhesion molecules as pharmaceutical target in atherosclerosis. Mini Rev. Med. Chem. 2012, 12:175-183.
66. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 2009, 8:23-33.
67. Ulbrich H., et al. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 2003, 24:640-647.
68. Joseph S.B., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7604-7609.
69. Bradley M.N., et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J. Clin. Invest. 2007, 117:2337-2346.
70. Levin N., et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 2005, 25:135-142.
71. Verschuren L., et al. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J. Lipid Res. 2009, 50:301-311.
72. Svensson S., et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22:4625-4633.
73. Williams S., et al. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J. Biol. Chem. 2003, 278:27138-27143.
74. Degoma E.M., Rader D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 2011, 8:266-277.
75. AIM-HIGH Investigators, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365:2255-2267.
76. Schwartz G.G., et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 2009, 158:896-901.
77. Voight B.F., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
78. Rader D.J., Tall A.R. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis?. Nat. Med. 2012, 18:1344-1346.
79. -/- mice. Am. J. Pathol. 2010, 177:493-500.
80. Döring Y., et al. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ. Res. 2012, 110:1052-1056.
81. Döring Y., et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012, 125:1673-1683.
82. Soehnlein O., et al. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J. Clin. Invest. 2008, 118:3491-3502.
83. Ionita M.G., et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1842-1848.
84. Naruko T., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002, 106:2894-2900.
85. Ylitalo R., et al. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J. Lab. Clin. Med. 1994, 123:769-776.
86. Stoneman V., et al. Monocyte/macrophage suppression in cd11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ. Res. 2007, 100:884-893.
87. Gautier E.L., et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009, 119:1795-1804.
88. Benítez M.B., et al. Endothelial and leukocyte adhesion molecules in primary hypertriglyceridemia. Atherosclerosis 2008, 197:679-687.
89. Han K.H., et al. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1983-1991.
90. Han K.H., et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005, 111:1439-1447.
91. Veillard N.R., et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006, 188:51-58.
92. Araujo F.B., et al. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis 1995, 117:61-71.
93. Mazor R., et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008, 197:937-943.
94. Broxmeyer H.E. Chemokines in hematopoiesis. Curr. Opin. Hematol. 2008, 15:49-58.
95. Broxmeyer H.E., et al. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and Gαi proteins and enhances engraftment of competitive, repopulating stem cells. J. Leukoc. Biol. 2003, 73:630-638.
96. Hwang J.H., et al. Interferon gamma has dual potential in inhibiting or promoting survival and growth of hematopoietic progenitors: interactions with stromal cell-derived factor 1. Int. J. Hematol. 2006, 84:143-150.
97. Broxmeyer H.E., et al. SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. Stem Cells Dev. 2007, 16:589-596.
98. Ottersbach K., et al. A310 helical turn is essential for the proliferation-inhibiting properties of macrophage inflammatory protein-1 alpha (CCL3). Blood 2006, 107:1284-1291.
99. Broxmeyer H.E., et al. Macrophage inflammatory protein (MIP)-1 beta abrogates the capacity of MIP-1 alpha to suppress myeloid progenitor cell growth. J. Immunol. 1991, 147:2586-2594.
100. Tall A.R., et al. Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2547-2552.